It was at an IACP conference in Florida, the largest event for police officers in the world, that Gergerian met Rick Doblin, the former hippie and founder of Maps (an acronym in English for “Multidisciplinary …
MDMA has been gaining attention for its potential therapeutic applications. In recent years, MDMA therapy, particularly MDMA-assisted psychotherapy, has been a topic of extensive research, with MAPS’ …
The code was the result of a partnership between U.K.-based COMPASS Pathways and the Multidisciplinary Association for Psychedelic Studies (MAPS) Public Benefit Corporation to facilitate access and insurance …
Quote Originally appearing here (Archived)
The bill – HD 2137, by state Rep. Nicholas Boldyga – was introduced in January, apparently in response to reporting by The Washington Post and The New York Times regarding moves by the nonprofit …
“Australia’s policy change is one that every country should consider: suffering people, regardless of nationality, need more opportunities to access novel treatments,” Rick Doblin, executive director …
FOR IMMEDIATE RELEASE: February 3, 2023 The Therapeutic Goods Administration (TGA) in Australia announced today that they will permit limited use of certain psychedelic-assisted therapies for the treatment …
The world's most advanced psychedelic-assisted therapy trial has confirmed positive findings in the second Phase 3 trial of MDMA-assisted therapy for PTSD.
MAPS Public Benefit Corporation (MAPS PBC) has announced that the final participant in the second Phase 3 trial of psychedelic-assisted therapy, A Multi-Site Phase 3 Study of MDMA-Assisted Therapy for …
FOR IMMEDIATE RELEASE: November 17, 2022 MAPS Public Benefit Corporation (MAPS PBC) has announced that the final participant in the second Phase 3 trial of psychedelic-assisted therapy, A Multi-Site Phase …
In September, the Training Team delivered two trainings for clinicians and behavioral health practitioners in MDMA-assisted therapy. One training was delivered September 12-18 at Stony Point Center in …
Enrollment continues in MPLONG, a long-term follow-up observational study for participants in MAPS-sponsored Phase 3 studies of MDMA-assisted therapy for the treatment of PTSD. You are eligible to participate …
